Device Trial Radar · NCT07765862
A Prospective, Randomized, Two-Arm, Controlled, Single-Blind, Multi-Center Study to Evaluate the Safety and Efficacy of ArtiFix® Dural Repair Sealant Graft in Cranial and Spine Surgery (NEOFIX Study)
Last checked: Nov 20, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
228
Planned (sponsor's estimate)
Start
Jan 1, 2027
Primary completion
Jan 1, 2029
Study completion Jan 1, 2029
Sponsor
- Lead sponsor
- Nurami Medical LtdAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Aug 14, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the NEOFIX study is to evaluate the safety and efficacy of ArtiFix® dural sealant graft in comparison to usual treatment for Dural repair (membrane that covers the brain and spinal cord) following cranial and spine surgeries. The investigated device will be implanted during the neurosurgical procedure and participants will be evaluated at 16, 36 and 120 days after the procedure.
Conditions
- CerebroSpinal Fluid (CSF) Leak
- Dural Tear
Interventions
ArtiFix® is a surgical dural sealant graft intended to close dural defects following cranial and spine surgeries.Device
ArtiFix® is a sterile, synthetic, single use, adhesive, resorbable sealant graft intended to seal and repair dural defects following cranial or spinal surgeries.
Standard of Care (Investigator Choice)Device
Standard-of-care for dural repair in spine or cranial procedures (only FDA cleared graft devices and approved sealants will be used)
Primary outcomes
What the sponsor says the trial is designed to measure.
- The absence of device-related CSF leakage or re-operation of the implantation site within 120 days after implantation.Time frame: at 120 days after ArtiFix® or control implantation
1 more outcomes with a free account
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.